Developing PsA: Risk Factors for Psoriasis Patients

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

IFPA World PsO and PsA Conference
IFPA World PsO and PsA Conference
Psoriasis
IFPA World PsO and PsA Conference
- Wilson Liao, MD
In The Pipeline: Phase 1, 2, and 3
In The Pipeline: Phase 1, 2, and 3
Psoriasis
In The Pipeline: Phase 1, 2, and 3
The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
Psoriasis
The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
- Jashin J. Wu, MD, FAAD
Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
Psoriasis
Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
- Jashin J. Wu, MD, FAAD
- Alexander Egeberg
- Priya Vedula Engel, MPH
- Sogol S. Javadi, BS
- Michael Korin
- Brandon Smith, BA